Close Menu

Drug Discovery & Development

News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.

Anetumab ravtansine was well tolerated and there was "a positive trend" suggesting that high mesothelin expression may indicate which cancer patients benefit from BAY 94-9343.

The company is testing out its immune-stimulating antibody conjugate platform technology, hitching its proprietary molecule to trastuzumab.

Tolero's investigational agent dubermatinib will be evaluated in AML patients who harbor a TP53 mutation and/or a complex karyotype.

In a study published in the Journal of Clinical Oncology, partial responses were observed in patients with BRAF V600-mutated and KRAS-mutated solid tumors.

The Chinese drug evaluation agency has granted the investigational new drug clinical trial authorization to taletrectinib in NRTK- and ROS1-mutated cancer patients.